Volume 15

Issue 1

Article 2

Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell
Transplantation
H Samarkandi
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia,
hsamarkandi61@kfshrc.edu.sa

M Al Nahedh
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

A Alfattani
Biostatistics Epidemiology and Scientific Computing Department, King Faisal Specialist Hospital and Research
Centre, Riyadh, Saudi Arabia

F Alsharif
Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

N Bakshi
Pathology and Laboratory Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi
Arabia
See next page for additional authors

Follow this and additional works at: https://www.hosct.org/hematology-oncology-and-stem-cell-therapy
Part of the Cancer Biology Commons, Hematology Commons, and the Oncology Commons

Recommended Citation
Samarkandi, H; Al Nahedh, M; Alfattani, A; Alsharif, F; Bakshi, N; Rasheed, W; Alfraih, F; Alhumaid, M; Alkhudair, Nora;
Alhayli, S; Alsaedi, H; Shaheen, M; Hanbali, A; Hashmi, S.K.; Devol, E; Alseraihy, A; Alzahrani, H; and Aljurf, M (2022)
"Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation," Hematology/Oncology
and Stem Cell Therapy: Vol. 15 : Iss. 1 , Article 2.
Available at: https://doi.org/10.1016/j.hemonc.2020.07.006
This Original Research Report is brought to you for free and open access by Hematology/Oncology and Stem Cell Therapy. It has
been accepted for inclusion in Hematology/Oncology and Stem Cell Therapy by an authorized editor of Hematology/Oncology
and Stem Cell Therapy.

Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell
Transplantation
Authors
H Samarkandi, M Al Nahedh, A Alfattani, F Alsharif, N Bakshi, W Rasheed, F Alfraih, M Alhumaid, Nora
Alkhudair, S Alhayli, H Alsaedi, M Shaheen, A Hanbali, S.K. Hashmi, E Devol, A Alseraihy, H Alzahrani, and
M Aljurf

This original research report is available in Hematology/Oncology and Stem Cell Therapy: https://www.hosct.org/
hematology-oncology-and-stem-cell-therapy/vol15/iss1/2

ORIGINAL RESEARCH REPORT

Evaluation of Eltrombopag in Thrombocytopenia Post
Hematopoietic Cell Transplantation: Rertrospective
Observational Trial
H. Samarkandi a,*, M. Al Nahedh a, A. Alfattani b, F. Alsharif c, N. Bakshi d, W. Rasheed c,
F. Alfraih c, M. Alhumaid g, Nora Alkhudair f, S. Alhayli c, H. Alsaedi e, M. Shaheen c,
A. Hanbali c, S.K. Hashmi c, E. Devol b, A. Alseraihy e, H. Alzahrani c, M. Aljurf c
a

Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Biostatistics Epidemiology and Scientiﬁc Computing Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi
Arabia
c
Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
d
Pathology and Laboratory Medicine Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
e
Pediatric Hematology/Oncology Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
f
Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
g
Oncology Centre, King Saud Medical City, Riyadh, Saudi Arabia
b

Abstract
Background: Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5e20%.
Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion
is the maintain stay of treatment. Eltrombopag is approved for the treatment of thrombocytopenia associated with
different diseases, however; data on eltrombopag treatment post HCT are limited.
Methods: This is a retrospective cohort study evaluating the effect of eltrombopag on platelet recovery in patients with
persistent thrombocytopenia post HCT. The primary endpoint was platelet recovery to ≥ 20,000/mL for 7 consecutive
days without transfusion support after starting eltrombopag. Secondary endpoint was platelet recovery to ≥ 50,000/mL
for 7 consecutive days.
Results: Twenty-one patients were included. Twelve (75%) of 16 patients became independent from platelet transfusions. Median time from starting eltrombopag to last transfusion was 60 days (range, 9e226 days). Ten (63%) of 16
transfusion dependent patients with platelet count < 20,000/mL achieved the primary endpoint. Seven (33%) patients of
21 included had successful platelet recovery (ie, ≥50,000/mL without transfusion support) and the median time to platelet
recovery in patients who achieved it was 32 days (range, 13e265 days). Ten patients (48%) were able to successfully
discontinue eltrombopag without recurrence of thrombocytopenia.
Conclusion: Our ﬁndings demonstrated that eltrombopag appears to have a clinically signiﬁcant impact on platelet
recovery in persistent thrombocytopenic patients post HCT.
Keywords: Eltrombopag, Thrombocytopenia, Hematopoietic cell transplant

1. Introduction

H

ematopoietic cell transplantation (HCT) is the
primary curative treatment option for several
hematologic malignancies and many other non-

neoplastic hematologic disorders [1]. Although this
procedure is effective and considered curative in
treating certain diseases [2], a considerable number
of complications occur during the HCT procedure.
Persistent thrombocytopenia is one of the serious
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complications reported post HCT with an incidence
of 5e20% [3e6]. Several mechanisms have been
proposed as contributing factors for post-HCT
thrombocytopenia including accelerated peripheral
platelet destruction secondary to platelet antibodies,
reduced number of marrow megakaryocytes,
engraftment failure, infections, myelosuppressive
effect of drugs, and disease relapse. Previous studies
also showed that late-onset thrombocytopenia can
be triggered by graft-versus-host disease [3e6].
Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT, and
platelet transfusion remains the mainstay treatment.
Persistent thrombocytopenia post HCT increases
the risk of bleeding which necessitates platelet
transfusion. Although it is crucial, multiple platelet
transfusions can be associated with serious complications including but not limited to hemolysis from
ABO-mismatched transfusions, acute lung injury,
bacterial sepsis, and thrombosis [7]. Post-HCT
thrombocytopenia is also associated with a higher
mortality rate, and its occurrence is considered as a
poor prognosis [8]. Additionally, the need for multiple and repeated platelet transfusions exhausts the
healthcare resources, thereby creating a signiﬁcant
cost burden on the healthcare system.
Two ﬁrst-generation thrombopoietin agents were
initially developed and used in the management of
chemotherapy-related
thrombocytopenia
[9].
Despite their success in increasing the platelet production, they are no longer used due to autoantibody
formation that leads to persistent thrombocytopenia.
In the following years, second-generation thrombopoietin agents (e.g., romiplostim and eltrombopag)
were developed and licensed for the treatment of
patients with idiopathic (immune) thrombocytopenic purpura (ITP) [9]. Their unique properties
have demonstrated potential for broader applications. Eltrombopag is an orally bioavailable, nonpeptide thrombopoietin receptor agonist (TPO-R)
that induces differentiation and proliferation of
megakaryocytes by activating the human TPO receptor. It is also approved in the treatment of
idiopathic aplastic anemia, chronic hepatitis C
infection-associated thrombocytopenia, and ITP.
Eltrombopag also reportedly reduced the burden of
thrombocytopenia and its associated complications
[10e22]. Until now, there is no treatment for postHCT thrombocytopenia and platelet transfusion
remains the only treatment option available.
Although the data is scarce regarding the use of
eltrombopag for post-HCT thrombocytopenia, the
possibility of a clinically signiﬁcant platelet recovery
has encouraged physicians to prescribe it in an
attempt to improve platelets.

Prior studies that reported the use of eltrombopag
comprised mainly case reports or small-sized prospective or retrospective studies [10e26]. In this
study we aim to assess the safety and efﬁcacy of
eltrombopag for patients with post-HCT thrombocytopenia in a large tertiary care center.

2. Methods
2.1. Study design
Based on the earlier studies aforementioned, we
hypothesized a reasonable efﬁcacy of eltrombopag
for patients with post-HCT thrombocytopenia,
without any moderate or severe adverse effects. This
retrospective cohort study was designed to evaluate
the effect of eltrombopag on platelet recovery in
patients with post-HCT thrombocytopenia. The
study was conducted at a single center which is one
of the largest HCT centers globally. Data were
collected from adult and pediatric patients post
HCT from 2014 to 2017. The study protocol was
approved by the Research Ethics Committee (Institute Review Board at KFSH&RC, Riyadh). Informed
consent was waived because of minimal risk associated with the retrospective study design.
2.2. Patients
All adult and pediatric patients who underwent
HCT and received eltrombopag for thrombocytopenia were screened. Patients were included if they
had post-HCT persistent thrombocytopenia as
either prolonged isolated thrombocytopenia (PIT) or
secondary failure of platelet recovery (SFPR). PIT
was deﬁned as dependence on platelet transfusion
for 30 days or longer after HCT. SFPR was deﬁned
as a decline of platelet count  20,000/mL lasting at
least 7 consecutive days or requiring platelet transfusion within 7 days after achieving primary platelet
recovery. Patients were excluded if they had secondary causes for thrombocytopenia such as
chronic hepatitis C infection-associated thrombocytopenia, ITP, and drug-induced thrombocytopenia (e.g., ganciclovir-, valganciclovir-, and
calcineurin inhibitor-induced thrombotic microangiopathy), or had persistent thrombocytopenia
secondary to graft failure.
2.3. Endpoints
The primary endpoint was platelet recovery
to  20,000/mL for 7 consecutive days without
transfusion support after starting eltrombopag
treatment. Secondary endpoints were platelet
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transfusion
independence,
platelet
recovery
to  50,000/mL for 7 consecutive days, number of
patients who tapered/stopped eltrombopag without
recurrence of thrombocytopenia after successful
platelet recovery, and platelet recovery based on
thrombocytopenia type (i.e., PIT or SFPR) and based
on the number of bone marrow megakaryocytes
before starting eltrombopag treatment if available.
Adverse events inducing hepatotoxicity deﬁned by
total bilirubin  1.5  upper limit of the normal
(ULN) or transaminase  3  ULN and thromboembolism occurred after eltrombopag was started.
2.4. Statistical analysis
All statistical analyses were performed using SPSS
Statistics for Mac version 22.0 (IBM, Armonk, NY,
USA). Categorical variables were presented as n (%),
whereas continuous variables were summarized as
the mean ± standard deviation or medians, range
and interquartile range when distributions were
skewed. Paired t test was used to assess the means
of platelets before and after eltrombopag. Categorical data were analyzed using Pearson’s chi-square
or Fisher exact tests were appropriate. A
KaplaneMeier curve was constructed to represent
the time to achieve platelet recovery. The p value
was set at 0.05 for all tests applied. Multivariate
analysis was not applied due to small sample size
and the possibility of underpowered estimates.

3. Results
3.1. Baseline characteristics
Out of 262 patients screened, 21 met the inclusion
criteria. Indications for HCT were acute lymphoblastic leukemia (n ¼ 5; 24%), acute myeloid leukemia (n ¼ 5; 24%), chronic myeloid leukemia (n ¼ 3;
14%), aplastic anemia (n ¼ 2; 9.5%), Hodgkin lymphoma (n ¼ 2; 9.5%), and other indications (n ¼ 4;
19%). The median patient age was 27 years (range,
7e58 years). Fifteen (71%) patients had allogeneic
HCT and six (29%) patients had autologous HCT.
All allogeneic transplant patients had HCT from a
related donor using peripheral blood stem cells with
median CD34 þ cells of 3.66  10(6)/kg, range
1.52e8  10(6)/kg.
Bone marrow aspiration was performed in 15
patients (71%) before starting eltrombopag treatment. Megakaryocytes were absent based on the
average of 0e2 megakaryocytes/high-power microscopic ﬁeld (HPF) in 3 (20%) patients and were
adequate based on the average of 2e4 megakaryocytes/HPF in 12 (80%) patients. Eltrombopag was

started in 16 patients with PIT and 5 patients with
SFPR. At the time of the analysis, 15 (71%) patients
were alive and 6 (29%) patients were deceased
(Table 1).
Before starting eltrombopag treatment, 16 (76%)
patients were dependent on platelet transfusions
and 5 (24%) patients were independent of platelet
transfusion. Eltrombopag was started at a median of
91 (31e787) days after HCT. The median administered dose of eltrombopag was 50 (25e150) mg daily.
Table 1. Characteristics of the cohort at baseline assessment.
Characteristic
Age (y)
Median (range)
Sex
Male
Female
Diagnosis
ALL
AML
CML
AA
HL
Others
Type of HCT
Allogeneic
Autologous
Donor
Related
Unrelated
Stem cell source
Peripheral blood stem cells
Bone marrow
Type of thrombocytopenia
PIT
SFPR
Prior Grade IeIV acute GvHD
Transfusion status pre eltrombopag
Dependent
Independent
Platelet count pre eltrombopag
Median ± SD
Patient status at the time of data collection
Alive
Deceased
Reason for death
Infections
Disease relapse
GvHD
Others
Megakaryocyte in bone marrow pre eltrombopag
Abundant
Adequate
Absent

N (%)
27 (7e58)
15 (71)
6 (29)
5
5
3
2
2
4

(24)
(24)
(14)
(9)
(10)
(19)

15 (71)
6 (29)
15 (100)
0 (0)
21 (100)
0 (0)
16 (76)
5 (24)
9 (43)
16 (76)
5 (24)
21 ± 17
15 (71)
6 (29)
2
2
0
2

(34)
(33)
(0)
(33)

0 (0)
12 (80)
3 (20)

Note. AA ¼ aplastic anemia; ALL ¼ acute lymphoblastic leukemia;
AML ¼ acute myeloid leukemia; CLL ¼ chronic lymphocytic
leukemia; CML ¼ chronic myeloid leukemia; GvHD ¼ graftversus-host disease; HCT ¼ hematopoietic cell transplantation;
HL ¼ Hodgkin lymphoma; PIT ¼ prolonged isolated thrombocytopenia; SD ¼ standard deviation; SFPR ¼ secondary failure of
platelet recovery.
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Fig. 1. A KaplaneMeier curve of the time from starting eltrombopag to
platelet recovery by days demonstrating the cumulative incidence of
platelet recovery to either  20,000/mL or  50,000/mL for 7 days
without platelet transfusion.

The median number of eltrombopag doses was 73
(11e594). Of the 16 transfusion-dependent patients,
12 (75%) became independent from platelet transfusions, whereas 4 (25%) patients remained dependent. The median time from starting eltrombopag to
the last transfusion was 60 (9e226) days. Of the 16
transfusion-dependent patients, 10 (63%) patients
with platelet count < 20,000/mL achieved the primary endpoint. Out of the 21 patients included, 7
(33%) had successful platelet recovery (i.e.,  50,000/
mL without transfusion support), and the median
time to platelet recovery in patients who achieved it
was 32 (13e265) days.
Ten patients (48%) were able to taper off eltrombopag without the recurrence of thrombocytopenia.
Among the 20 patients who completed the course,
the median total duration of treatment was 2.9

(0.7e19.9) months. The cumulative incidence of
platelet recovery to either  20,000/mL or  50,000/
mL for 7 days, without platelet transfusion, is 57%
(95% conﬁdence interval [CI] ¼ 36e75%) as shown
in Fig. 1. Platelet recovery occurred in 75% and 40%
patients with PIT and SFPR, respectively. The results are shown in Table 2. The platelet count has
been increased by 31 units (95% CI ¼ 19e42.7) after
using eltrombopag. A paired sample correlation was
done that showed platelet recovery following
eltrombopag. Mean platelet count was 21 ± 17 and
52 ± 30 before and after eltrombopag, respectively,
which was statistically signiﬁcant ( p ¼ .003; Fig. 2).
Eltrombopag was well tolerated, and no patient
discontinued the drug because of adverse events.
No patient developed liver toxicity or thrombosis.

4. Discussion
In our retrospective study, eltrombopag was
shown to be effective and well tolerated in the

Fig. 2. Difference of means of platelet count before and after
eltrombopag.

Table 2. Outcomes of the Cohort After Follow-up.
Characteristic
Maximum dose of eltrombopag, median (range)
 1st dose change
 2nd dose change
 3rd dose change
Platelet count post eltrombopag
Median ± SD
Duration from starting eltrombopag to platelet recovery (20,000/mL or  50,000/mL), median (range), d
Achievement of transfusion independence
 Yes
 No
 Never transfusion dependent
Time from starting eltrombopag to last transfusion, median (range), d
Days from starting eltrombopag to platelet  50,000/mL, median (range), d
Status of thrombocytopenia at the last follow-up
 Transfusion independent without eltrombopag
 Transfusion independent with eltrombopag
 Transfusion dependent
Note. SD ¼ standard deviation.

n
75 (50e100)
50 (25e150)
50 (25e100)
52 ± 30
68 (13e175)
12 (75)
4 (25)
5 (24)
60 (9e226)
32 (13e265)
10 (48)
1 (4)
10 (48)

Table 3. Literature Review.
Study design

Population

N

Transplant

Cause of
thrombocytopenia

Transfusion
independent

Treatment duration

Time from start of eltrombopag
to platelet ≥ 50,000/mL

Reid et al. [19]

Case report

Adult

2

Allogeneic

Achieved (n ¼ 2)

6 wk and 28 mo

Not achieved

Fujimi et al. [18]

Case report

Adult

1

Allogeneic

Achieved

30 mo

Not reported

Dyba et al. [11]

Case report

Adult

1

Allogeneic

Achieved

15 mo

Not reported

Ferrarini et al. [12]

Case report

Adults

1

Allogeneic

Achieved

3 mo

30 d

Ali et al. [13]

Case report

Child

1

Allogeneic

Achieved

10.7 mo

12 wk

Master et al. [14]

Case report

Adults

1

Allogeneic

Achieved

12 mo

18 d

Raut et al. [15]

Retrospective

Adult

12

Achieved (n ¼ 12)

Median, 29 d

Not reported

Ma et al. [20]

Retrospective

Adults

10

Autologous/
Allogeneic
Allogeneic

Achieved (n ¼ 5)

Not reported

Median, 16 d (range, 10e56 d)

Tanaka et al. [10]

Retrospective

Adult

12

Allogeneic

Prolonged platelet
recovery
Prolonged platelet
recovery
Prolonged platelet
recovery
Secondary failure
of platelet recovery
Prolonged platelet
recovery
Prolonged platelet
recovery
Prolonged platelet
recovery
Prolonged platelet
recovery
PIT/SFPR

Achieved (n ¼ 8)

54 d

Mori et al. [16]

Retrospective

Adults

19

Fu et al. [25]

Retrospective

38

Prolonged platelet
recovery
PIT/SFPR

Achieved (n ¼ 23)

Yuan et al. [26]
Rivera et al. [27]

Retrospective
Retrospective

Adults/
pediatrics
Adults
Adults

Autologous/
Allogeneic
Allogeneic

Median, 136
(range, 52e244) d
Not reported

13
467

Allogeneic
Allogeneic

PIT/SFPR
PIT/SFPR

Achieved (n ¼ 8)
Not reported

Achieved (n ¼ 14)

Median, 64
(range 14e195) d
Not reported
Median, 21 (9e93)
d93 days)

Median, 41 d (range, 11e93 d)
Median, 32 d (range, 7e127 d)
Median, 33 d (range 11e68 d)
Median, 91 d (8e206 d)
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Note. PIT ¼ prolonged isolated thrombocytopenia; SFPR ¼ secondary failure of platelet recovery.
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management of patients with persistent thrombocytopenia post HCT. Eltrombopag had a statistically
signiﬁcant impact on platelet count, with 48% patients remaining independent from platelet transfusion at their last follow-up visit without
thrombocytopenia recurrence.
Post-HCT thrombocytopenia occurs in 5e20% of
patients with more than 3 months’ dependency on
platelet transfusion [15e20]. The reason for low
platelet count post HCT is still unclear, but
increased platelet turnover, platelet destruction, and
impaired thrombopoiesis are some of the proposed
mechanisms [5]. The rationale behind using
eltrombopag is to accelerate platelet recovery
through stimulating hematopoiesis by mimicking
natural TPO. Additionally, eltrombopag increases
the platelet lifespan by preventing platelet apoptosis
[21].
A Phase I dose-escalation study by Liesveld et al.
[22] reported the use of eltrombopag in 19 patients
who underwent HCT post total body irradiation.
Eltrombopag was started prophylactically 24e48
hours post transplantation with escalating doses as
tolerated [22]. No dose-limiting toxicities were reported. However, one episode of pulmonary embolism and one catheter-related clot was reported,
whereas none were observed in our patient cohort.
In a Phase II randomized, double-blind, placebocontrolled study by Popat et al. [23], the use of
eltrombopag in post-HCT thrombocytopenia
showed a probable superior response rate
compared with placebo. However, the results were
published in an abstract and the full article publication is eagerly awaited as it is the only randomized trial on the use of eltrombopag in this setting
(ClinicalTrials.gov number, NCT01000051).
Table 3 provides a summary of the previously
published reports regarding the use of eltrombopag
in post-HCT thrombocytopenia. These reports have
described a total of 578 patients who were treated
with eltrombopag post HCT. Eltrombopag doses
ranged from 12.5 mg to 100 mg daily. In total 77
patients responded and became platelet transfusion
independent. Eltrombopag was well tolerated with
no evidence of Grades 3e4 toxicities in most of the
studies. A recently published review article gave an
overview of TPO-Rs biology and summarized
studies that used them to treat prolonged thrombocytopenia post HCT [24].
Reportedly, prolonged thrombocytopenia and
slow platelet engraftment after allo-HCT may be
related to a reduction in ploidy and immaturation of
megakaryocytes [6]. Fu et al. [25] found that the
presence of megakaryocytes in the bone marrow
before starting eltrombopag better predicted the

efﬁcacy of eltrombopag than the type of thrombocytopenia after haplo-HCT.
Although the study demonstrated the efﬁcacy of
eltrombopag, it has several limitations. This was a
retrospective observational study with no control
arm, which may have inﬂuenced the accuracy of our
ﬁndings. Second, the cohort size was small and
therefore no associations could be analyzed. Further
prospective randomized comparative studies are
warranted to conﬁrm the efﬁcacy of eltrombopag.
In summary, eltrombopag resulted in the recovery
of platelet count without transfusion support and
reported side effects. Eltrombopag may be used
successfully in the management of persistent
thrombocytopenia post HCT. The results of this and
other published prospective studies need to be
validated in other larger studies optimally in a
randomized controlled design.
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